Primary liver transplantation vs liver resection followed by transplantation for transplantable hepatocellular carcinoma: Liver functional quality and tumor characteristics matter

Mehmet Fatih Can, Christopher B Hughes

Abstract
Liver resection (LR) and primary liver transplantation (LT) are two potentially curative treatment modalities for patients with hepatocellular carcinoma (HCC). If an underlying chronic liver disease exists, however, making a decision on which method should be selected is difficult. If a patient has no chronic liver disease, LR may be the preferable option with salvage transplantation (ST) in mind in case of recurrence. Presence of a moderate-to-severe liver failure accompanying HCC usually warrants primary LT. The treatment of patients with HCC and early-stage chronic liver disease remains controversial. The advantages of "LR-followed-by-ST-if-needed" strategy include less complicated index operation, no need for immunosuppression, use of donor livers for other patients in today’s organ shortage setting and comparable survival rates. However, primary LT has its own advantages as it also treats underlying chronic liver disease with carcinogenic potential, removes undetected tumor nodules and potentially eliminates need for a ST. An article recently published by Fuks et al in Hepatology offers an approach by which selecting between LR-followed-by-ST and immediate LT might be easier. Here we discuss the results of the aforementioned report in the light of currently available knowledge.

Key words: Hepatocellular carcinoma; Chronic liver disease; Liver transplantation; Liver resection; Salvage transplantation; Survival

Can MF, Hughes CB. Primary liver transplantation vs liver resection followed by transplantation for transplantable hepatocellular carcinoma: Liver functional quality and tumor characteristics matter. World J Gastrointest Surg 2013; 5(1): 5-8 Available from: URL: http://www.wjgnet.com/1948-9366/full/v5/i1/5.htm DOI: http://dx.doi.org/10.4240/wjgs.v5.i1.5

COMMENTARY ON HOT TOPICS
Liver transplantation (LT) remains the most effective treatment modality for patients with hepatocellular carcinoma (HCC) and underlying chronic liver disease provided that the procedure can be justified by a potentially curable tumor stage. In today’s Model for End-Stage Liver Disease (MELD) based practice, Milan Criteria (MC) (one lesion < 5 cm or up to three lesions each < 3 cm with the disease confined to the liver) constitute the main parameter by which to predict patients who would benefit most from LT[1]. While the incidence of HCC is believed to have an increasing trend likely parallel to the increasing number of patients who have had a long lasting course of viral hepatitis infection[2], global donor organ shortage continues to be the most important issue for patients on wait lists as well as for health care providers in the field. This has led the surgery community to look at liver resec-
tion (LR) as a comparable alternative treatment. Patients could be treated by LR followed by the so-called “salvage transplantation” (ST) in cases of tumor recurrence or hepatic decompensation. This would also help the community and other transplant candidates to gain maximum possible benefit from organs of deceased donors. Indeed, thousands of patients have undergone LR as a result of the adoption of this policy over the last decade, and many of them survived subsequent LT. However, this strategy must be carefully evaluated, as there is no guarantee that every patient with HCC undergoing an initial LR with ST in mind will have recurrent disease within the indications of LT. ST may not be an option if: (1) the recurrence is beyond MC; or (2) the patient has developed contraindications to LT, such as advanced age or medical comorbidities. In addition to these factors, the technical challenges of LT will likely be increased in a patient having undergone previous hepatic resection due to scarring and vascularized adhesions.

Bridge therapy, defined as LR followed by a planned LT, regardless of whether the disease recurs, is another strategy to treat HCC. This approach significantly reduces the chance of progression while awaiting an appropriate organ; the strategy is considered to have become successful if a donor liver is offered by the organ allocation system before the patient drops off of the list due to non-transplantable disease recurrence. However, it has been reported that this approach may be associated with greater technical difficulty during transplantation[1][2], particularly if the hepatic hilum and the peri-caval area were dissected extensively during the preceding LR. One other downside to use of LR as bridge therapy is that, in the United States for example, resection of HCC removes the opportunity to use that tumor to gain extra MELD points as a “MELD exception”.

For the aforementioned reasons, management of patients with chronic liver disease accompanied by transplantable HCC is an ongoing controversy, leading researchers to seek reliable measures by which to discriminate patients who would benefit from its initial LR from those patients for whom LT should be the first-line treatment.

HOT TOPIC ARTICLE

Fuks et al[3] recent study published in Hepatology in January 2012 may have the potential to provide a new insight into the issue. Looking to clarify this controversy, the authors compared the outcomes of patients (n = 138) who underwent LR for transplantable HCC within MC, considering ST in case of recurrence, with those of patients who were primarily listed to undergo LT (n = 191). They performed an intent-to-treat based analysis to reveal independent predictors of failure to receive timely ST after initial LT. Out of 138 patients who were supposed to undergo ST in case of recurrence, 26 were excluded because they either underwent LT before recurrence or were diagnosed with a different disease based on final histology. Thus, only 112 patients were planned for ST. Of these, 90 had recurrent disease, of which 30 (33%) did not receive ST because of a recurrence outside the MC. Of remaining 60 patients with recurrence within MC, 21 were not eligible to undergo a major transplant surgery, leaving only 39/90 patients (44%) successfully receiving ST. In the primary LT group, 163 patients underwent LT. After excluding early postoperative deaths and histological diagnoses other than HCC based on explant pathology, this group finally had 146 patients who received a successful LT for HCC. What we can conclude from the results are: (1) One fifth of patients in the initial LR group survived recurrence free. None of those patients required LT for any reason during follow-up; (2) While the median follow-up of whole study population was about 5 years, recurrences (if any) occurred usually much earlier. The median time to recurrence was around 16 mo and was similar in patients regardless of whether they had a recurrent disease within MC or outside MC; (3) The overall 1, 3 and 5-year survival in patients undergoing ST was 94%, 81% and 71%, respectively. The two most frequent reasons for not receiving a ST in within MC group were patient refusal (n = 10) and advanced age (n = 9); (4) In the group beyond MC, tumor > 5 cm, number of lesions > 3 and major vascular involvement were the most frequent contraindications for a ST, occurring in 8 patients each; (5) Multivariate analysis revealed five factors independently associated with recurrence beyond MC: microscopic vascular invasion, presence of satellite nodules, tumor size > 3 cm, poor tumoral differentiation, and existence of cirrhosis. The authors suggested that presence of ≥ 3 poor prognostic factors should warrant LT before recurrence; (6) ST strategy seemed to save 26 grafts which would otherwise have been used unnecessarily; and (7) However, as a result of this strategy, only 28% of patients included in intention-to-treat analysis and only 39% of patients with recurrence could receive ST, suggesting that primary LT rather than “LR followed by ST if needed” strategy should be the treatment of choice in most of patients with HCC and underlying chronic liver disease.

DISCUSSION

We believe that some important points should be taken into consideration when evaluating the results of this study. As the authors stated in part, a selection bias could not completely be eliminated in this study. All patients in the LR followed by ST group had quite good liver function as determined by having Child-Pugh class A disease and significantly lower mean MELD score (6.5 vs 19.8) compared to those in primary LT group. In addition, none of the patients in the earlier group had portal hypertension or reduced thrombocyte count. Moreover, the proportion of patients with Metavir score of F3 in that group was lower than that in the primary LT group. This data suggests that the severity of underlying liver disease was the main parameter to decide the surgical approach selected to manage patients. This kind of study design may be considered inevitable, however, for comparison
of LT with subsequent ST vs LT, as implemented by Facciotto et al\[3\] in their retrospective study. Similarly, the average Child-Pugh score and MELD score were lower in the primary LR subsequent ST group than in the primary LT group, though they did not include Child-Pugh class C patients in their analysis. Of 51 patients with HCC undergoing LR as initial treatment, 32 developed recurrence. However, 21 (66%) of those were not eligible to receive ST. Tumor size > 3 cm and high MELD score were shown to be independent risk factors indicating poor survival. There was no difference between the groups in 1- and 4-year overall survival. In a study by Shah et al\[7\], patients with Child-Pugh class A and B disease and HCC within MC were treated by either initial LR (n = 121) or listed for primary LT (n = 140). The drop-out rate in the primary LT group was 21.4% (30 patients). There was no information reporting the number of patients who could undergo ST due to recurrence in the LR group. The authors concluded that primary LT yields better overall survival compared to LR if waiting time from listing for LT was < 4 mo. Of note, histological examination of explants in the primary LT group revealed that 46% of patients actually had a disease outside MC. Margarit et al\[8\] reported that only 6 out of 18 patients with recurrence after LR were able to undergo ST during a 50-mo median follow-up.

Fuks et al\[3\] included only patients within MC. Despite adoption of these criteria by the United Network for Organ Sharing as well as by the majority of centers outside the United States as an integral part of liver allocation systems, some authors have reported that University of California San Francisco (UCSF) criteria (one tumor < 6.5 cm, maximum of 3 tumors with none > 4.5 cm, and cumulative tumor size < 8 cm) can also be used reliably and could yield a long-term outcome comparable to MC\[9,10\]. However, expanding the inclusion criteria beyond the UCSF model resulted in worse survival compared to meeting UCSF criteria\[9,10\]. It has to be highlighted that a tumor is likely to result in a drop-out from waiting lists as a waiting list death if it has aggressive histological and genetic features. Perhaps favorable outcomes yielded in patient groups within UCSF criteria result from a relatively good nature of histology despite the tumor size exceeding MC. We don’t know what would have happened if Fuks et al\[3\] had included patients within UCSF criteria in LR and primary LT groups. Similarly, we do not have any information about how many of patients who had a recurrence beyond MC after initial LR (n = 30) met the UCSF criteria and what would have been the long-term results if those patients had undergone ST.

Another important point is that the study by Fuks et al\[3\] did not evaluate if it was possible to throw off an unnecessary LR by proceeding directly to LT in the presence of pejorative factors in patients with early stage chronic liver disease. While preoperative imaging by today’s state of the art technology is the mainstay of decision making process when planning the treatment of malignant liver tumors, there may yet be valuable information obtained from histological evaluation of tissues taken by minimally invasive techniques. The main concern with regard to fine-needle aspiration cytology or core biopsy is that the intervention may cause significant bleeding and tumor seeding. Although much of the evidence is anecdotal, a few reports have suggested that fine needle aspiration cytology or core biopsy be avoided due to tumor seeding risk up to 5%\[12-14\]. The risks and benefits of preoperative biopsy may need to be reassessed in the future given newly recognized advantages attributed to histological evaluation. In fact, DuBay et al\[15\] recently proposed “Toronto Criteria” in which preoperative biopsy is used as a guide when deciding exclusion of patients beyond MC from wait list. They reported that outcomes comparable to those of patients meeting MC could be achieved if histological findings demonstrate well-differentiated carcinoma. Cillo et al\[16\] reported that tumor differentiation was one of the strongest predictors of biological aggressiveness and therefore recurrence, suggesting that preoperative detection of tumor grade would be of importance in deciding the type of treatment modality. In the study by Fuks et al\[3\], 30 patients treated with curative-intent LR failed to receive ST due to recurrence outside MC. If this result could have been predicted before LR, those patients likely would have undergone immediate LR. Nonetheless, it has to be stated that the nature of their study was not suitable for such an evaluation.

In light of these data, there should be little argument on severe treatment of patients with HCC who have no underlying chronic liver disease as well as for those who have severe accompanying cirrhosis. What remains controversial is how to manage the patient with HCC developed on a background of Child-Pugh class A disease. In this context, we believe the conclusion drawn in the article by Fuks et al\[3\] should be paid attention. Primary LT may be a more logical modality as it has the capability of treating the disease while reducing the risk of recurrence by eliminating carcinogenic fibrotic liver tissue as well as the underlying condition. Some oncological parameters and unfavorable histological factors such as tumor size, microscopic invasion of vessels, presence of satellite nodules not detected by preoperative imaging, the real severity of cirrhosis, and differentiation of carcinoma should be taken into account if resection is to be selected as the first-line treatment. If a patient presents with tumor within MC, but histological factors, either by resection or biopsy, suggest recurrence may be more aggressive after LR and may ultimately exclude the option of ST, then LT should be the primary consideration.

REFERENCES

1. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. *Liver Transpl* 2011; 17 Suppl 2: S44-S57 [PMID: 21695773 DOI: 10.1002/lt.22365]

2. Altekruse SF, Mcclay KA, Reichman ME. Hepatocellu-
Can MF et al. Primary vs Salvage liver transplantation after resection for HCC

lcar carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491 [PMID: 19224838 DOI: 10.1200/JCO.2008.20.7753]

3 Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 2003; 238: 508-18; discussion 518-9 [PMID: 14530722]

4 Panaro F, Piardi T, Cag M, Cinqualbre J, Wolf P, Audet M. Robotic liver resection as a bridge to liver transplantation. JSLS 2011; 15: 86-89 [PMID: 21902950 DOI: 10.4293/108680 11X13022985131417]

5 Fuku D, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 2012; 55: 132-140 [PMID: 21932387 DOI: 10.1002/hep.24680]

6 Facciuto ME, Rochon C, Pandey M, Rodriguez-Davalos M, Samaniego S, Wolf DC, Kim-Schluger L, Rozenblit G, Sheiner PA. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. HPB (Oxford) 2009; 11: 398-404 [PMID: 19768144 DOI: 10.1111/j.1477-2574.2009.00073.x]

7 Shah SA, Cleary SP, Tan JC, Wei AC, Gallinger S, Grant DR, Greig PD. An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. Ann Surg Oncol 2007; 14: 2608-2614 [PMID: 17522942 DOI: 10.1245/s10434-007-9443-3]

8 Margarit C, Escartin A, Castells L, Vargas V, Allende E, Bilbao I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl 2005; 11: 1242-1251 [PMID: 16184539]

9 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-59; discussion 502-59; [PMID: 17717454]

10 Decaes T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boilott O, Sulpice L, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Cherqui D, Duvoux C. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006; 12: 1761-769 [PMID: 16964590 DOI: 10.1011/iit.20884]

11 Unek T, Karademir S, Arslan NC, Egeli T, Atasoy G, Sagol O, Obuz F, Akarsu M, Astarcioğlu I. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4206-4212 [PMID: 22072852 DOI: 10.3748/wjg.v17.i37.4206]

12 Souto E, Gores GJ. When should a liver mass suspected of being a hepatocellular carcinoma be biopsied? Liver Transpl 2000; 6: 73-75 [PMID: 10648581 DOI: 10.1011/iit.500060108]

13 Takamori R, Wong LL, Dang C, Wong L. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transpl 2000; 6: 67-72 [PMID: 10648580 DOI: 10.1011/iit.500060103]

14 Assy N, Nasser G, Djibre A, Beniashvili Z, Elias S, Zidan J. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol 2009; 15: 3217-3227 [PMID: 19598296 DOI: 10.3748/ wjg.v15.i1.3217]

15 DuBay D, Sandroussi C, Sandhu L, Cleary S, Guha M, Cat- ral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocella- r carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg Oncol 2011; 253: 166-172 [PMID: 21294289 DOI: 10.1097/SLA.0b013e31820508f1]

16 Cillo U, Vitale A, Bassanelli M, Boccagni P, Brolese A, Zarus G, Burra P, Fagioli S, Farinati F, Rugge M, D’Amico DF. Liver transplantation for the treatment of moderately or well-differ- entiated hepatocellular carcinoma. Ann Surg 2004; 239: 150-159 [PMID: 14748521 DOI: 10.1097/01.sla.0000109146.72827.76]